Company registration number 05572535 (England and Wales)
PCR HOLDINGS LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PCR HOLDINGS LIMITED
COMPANY INFORMATION
Directors
Mr P C Richardson
Mr G Ablett
Mr D J Richardson
Miss E L Richardson
Secretary
Mr P G Flintoft
Company number
05572535
Registered office
Courville House
34 Ellerbeck Court
Stokesley Business Park
Stokesley
North Yorkshire
TS9 5PT
Auditor
Davies Tracey
Swan House
Westpoint Road
Teesdale Business Park
Stockton on Tees
TS17 6BP
PCR HOLDINGS LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2 - 3
Independent auditor's report
4 - 6
Group statement of comprehensive income
7
Group balance sheet
8
Company balance sheet
9
Group statement of changes in equity
10
Company statement of changes in equity
11
Group statement of cash flows
12
Notes to the financial statements
13 - 27
PCR HOLDINGS LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 1 -

The directors present the strategic report for the year ended 31 March 2025.

Review of the business

The group's former principal activities of building and repairing industrial chimneys have been complemented in recent years by successful repositioning into an expanding role as specialist main contractors within the nuclear, rail, highways and petrochemical infrastructure maintenance industries.

 

The principal risks and uncertainties facing the group are of a general nature, such as a downturn in the UK economy or changes in government policy or thinking in connection with the infrastructure industry sectors in which the group operates, together with normal business risks relating to tendering for, performance of, and renewal of, contracts.

 

The directors regard the financial key performance indicators of the group to be the level of, and movement in, shareholders' funds and the profit for the financial year. The directors also regard the overall progress of long-term contracts and the health of the order book as significant to the development of the group.

 

The group had a successful year ended 31 March 2025. Additional orders for ongoing services and long-term contracts, particularly overseas, were secured. Major long-term contracts progressed well during the year. The group continues to develop new and innovative engineering solutions in its field of operations, and is taking major steps to expand its overseas operations.

 

Profit for the year ended 31 March 2025 was £1,242,021 (2024: £1,404,039) and shareholders' funds stood at £13,657,876 at 31 March 2025 (2024: £12,415,849).

 

The trading results for the year and the group's financial position at the end of the year are shown in the attached financial statements.

 

Indications at the present time show that the group should in the current year increase the value of the shareholders' funds, notwithstanding the longer term challenges the group may face in relation to the renewal of existing contracts.

 

On behalf of the board

Mr P C Richardson
Director
12 December 2025
PCR HOLDINGS LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -

The directors present their annual report and financial statements for the year ended 31 March 2025.

Principal activities

The principal activities of the company and group continued to be those of specialist main contractors within the nuclear, rail, highways and petrochemical infrastructure maintenance industries.

Results and dividends

The results for the year are set out on page 7.

No ordinary dividends were paid during the year. The directors do not propose payment of a dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mrs T B Richardson
(Resigned 16 April 2024)
Mr P C Richardson
Mr G Ablett
Mr D J Richardson
Miss E L Richardson
Statement of directors' responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure in the Strategic Report

The truegroup has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the group's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

PCR HOLDINGS LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
On behalf of the board
Mr P C Richardson
Director
12 December 2025
PCR HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF PCR HOLDINGS LIMITED
- 4 -
Opinion

We have audited the financial statements of PCR Holdings Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

PCR HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF PCR HOLDINGS LIMITED
- 5 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is the extent to which an audit conducted under ISAs (UK) is capable of detecting irregularities, including fraud. Our procedures include:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. We are not responsible for preventing fraud or non-compliance with laws and regulations and cannot be expected to detect all fraud and non-compliance with laws and regulations.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

PCR HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF PCR HOLDINGS LIMITED
- 6 -

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Craig McBride (Senior Statutory Auditor)
for and on behalf of Davies Tracey
Chartered Accountants and Statutory Auditors
Swan House
Westpoint Road
Teesdale Business Park
Stockton on Tees
TS17 6BP
29 December 2025
PCR HOLDINGS LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
2025
2024
Notes
£
£
Turnover
3
12,251,193
11,487,285
Raw materials and consumables
(1,553,820)
(1,710,981)
Other external expenses
(2,247,087)
(2,359,358)
Staff costs
5
(5,812,102)
(4,851,914)
Depreciation
4
(113,338)
(119,004)
Other operating expenses
(1,202,375)
(1,093,456)
Operating profit
4
1,322,471
1,352,572
Interest receivable and similar income
7
239,315
124,569
Profit before taxation
1,561,786
1,477,141
Tax on profit
8
(319,765)
(73,102)
Profit for the financial year
1,242,021
1,404,039
Profit for the financial year is all attributable to the owners of the parent company.
Total comprehensive income for the year is all attributable to the owners of the parent company.
PCR HOLDINGS LIMITED
GROUP BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 8 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
-
0
-
0
Tangible assets
11
1,734,488
1,778,480
1,734,488
1,778,480
Current assets
Stocks
14
21,458
18,095
Debtors
15
2,177,164
5,021,162
Cash at bank and in hand
11,191,114
8,245,591
13,389,736
13,284,848
Creditors: amounts falling due within one year
16
(1,333,410)
(2,520,504)
Net current assets
12,056,326
10,764,344
Total assets less current liabilities
13,790,814
12,542,824
Provisions for liabilities
Deferred tax liability
17
132,938
126,975
(132,938)
(126,975)
Net assets
13,657,876
12,415,849
Capital and reserves
Called up share capital
19
44,032
44,032
Other reserves
115,968
115,968
Profit and loss reserves
13,497,876
12,255,849
Total equity
13,657,876
12,415,849
The financial statements were approved by the board of directors and authorised for issue on 12 December 2025 and are signed on its behalf by:
12 December 2025
Mr P C Richardson
Mr G Ablett
Director
Director
Company registration number 05572535 (England and Wales)
PCR HOLDINGS LIMITED
COMPANY BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 9 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
11
1,185,085
1,173,753
Investments
12
44,033
44,033
1,229,118
1,217,786
Current assets
Cash at bank and in hand
2,130,669
2,034,455
Creditors: amounts falling due within one year
16
(35,277)
(16,809)
Net current assets
2,095,392
2,017,646
Total assets less current liabilities
3,324,510
3,235,432
Provisions for liabilities
Deferred tax liability
17
42,571
39,657
(42,571)
(39,657)
Net assets
3,281,939
3,195,775
Capital and reserves
Called up share capital
19
44,032
44,032
Profit and loss reserves
3,237,907
3,151,743
Total equity
3,281,939
3,195,775

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £86,164 (2024 - £171,020 profit).

The financial statements were approved by the board of directors and authorised for issue on 12 December 2025 and are signed on its behalf by:
12 December 2025
Mr P C Richardson
Mr G Ablett
Director
Director
Company registration number 05572535 (England and Wales)
PCR HOLDINGS LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 10 -
Share capital
General reserve
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 April 2023
44,032
100,000
15,968
10,939,873
11,099,873
Year ended 31 March 2024:
Profit and total comprehensive income
-
-
-
1,404,040
1,404,040
Dividends
9
-
-
-
(88,064)
(88,064)
Balance at 31 March 2024
44,032
100,000
15,968
12,255,849
12,415,849
Year ended 31 March 2025:
Profit and total comprehensive income
-
-
-
1,242,027
1,242,021
Balance at 31 March 2025
44,032
100,000
15,968
13,497,876
13,657,876
PCR HOLDINGS LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 11 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 April 2023
44,032
3,068,787
3,112,819
Year ended 31 March 2024:
Profit and total comprehensive income for the year
-
171,020
171,020
Dividends
9
-
(88,064)
(88,064)
Balance at 31 March 2024
44,032
3,151,743
3,195,775
Year ended 31 March 2025:
Profit and total comprehensive income
-
86,164
86,164
Balance at 31 March 2025
44,032
3,237,907
3,281,939
PCR HOLDINGS LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2025
- 12 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
24
2,789,255
841,290
Income taxes paid
(13,701)
-
0
Net cash inflow from operating activities
2,775,554
841,290
Investing activities
Purchase of tangible fixed assets
(97,258)
(221,502)
Proceeds from disposal of tangible fixed assets
27,912
3,601
Interest received
239,315
124,569
Net cash generated from/(used in) investing activities
169,969
(93,332)
Financing activities
Dividends paid to equity shareholders
-
0
(88,064)
Net cash used in financing activities
-
(88,064)
Net increase in cash and cash equivalents
2,945,523
659,894
Cash and cash equivalents at beginning of year
8,245,591
7,585,697
Cash and cash equivalents at end of year
11,191,114
8,245,591
PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 13 -
1
Accounting policies
Company information

PCR Holdings Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is Courville House, 34 Ellerbeck Court, Stokesley Business Park, Stokesley, North Yorkshire, TS9 5PT.

 

The group consists of PCR Holdings Limited and all of its subsidiaries.

1.1
Accounting convention

These consolidated financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company and the group. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:

 

1.2
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company PCR Holdings Limited together with all entities controlled by the parent company (its subsidiaries).

 

All financial statements are made up to 31 March 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

1.3
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 14 -
1.4
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

Turnover in respect of long-term contracts for services is ascertained in a manner appropriate to the stage of completion of the contract using a method that measures most reliably the work performed. In relation to long-term contracts for services entered into in foreign currencies, relevant exchange rate differences and movements are considered as part of the method measuring the work performed.

1.5
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 3 years.

1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold property
- not depreciated
Short leasehold property
- over 15 years
Plant and Tackle
- over 8 years
Office fittings & equipment
- over 8 years
Motor vehicles
- over 4 years

No depreciation is provided on freehold property as it is maintained to ensure that the value does not diminish over time and any depreciation charge would be immaterial. The maintenance costs are charged to profit and loss in the year incurred. Costs relating to premises on a customer's site (included within freehold property) are depreciated over 15 years.

1.7
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 15 -
1.9
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 16 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.10
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 17 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Operating lease rentals are charged to the profit and loss account on a straight-line basis over the term of the lease.

1.15
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

Government grants relating to turnover are recognised as income over the periods when the related costs are incurred. Grants relating to an asset are recognised in income systematically over the asset's expected useful life. If part of such a grant is deferred it is recognised as deferred income rather than being deducted from the asset's carrying amount.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.17

Research and development

Research and development expenditure is written off in the year it is incurred.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 18 -
2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Turnover and other revenue
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
10,943,629
8,871,018
Rest of the World
1,307,564
2,616,267
12,251,193
11,487,285
2025
2024
£
£
Other revenue
Interest income
239,315
124,569
4
Operating profit
2025
2024
£
£
Operating profit for the year is stated after charging/(crediting):
Fees payable to the group's auditor for the audit of the group's financial statements
10,850
10,350
Depreciation of owned tangible fixed assets
141,247
122,281
Profit on disposal of tangible fixed assets
(27,909)
(3,277)
Operating lease charges
93,414
79,170
PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 19 -
5
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
Administrative staff
11
11
-
-
Building operatives
69
57
-
-
Restaurant and bar staff
19
20
-
-
Total
99
88
-
0
-
0

Their aggregate remuneration comprised:

Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
5,102,038
4,264,042
-
0
-
0
Social security costs
508,143
425,639
-
-
Pension costs
201,921
162,233
-
0
-
0
5,812,102
4,851,914
-
0
-
0
6
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
473,356
454,388
Company pension contributions to defined contribution schemes
68,803
52,470
542,159
506,858
Remuneration disclosed above includes the following amounts paid to the highest paid director:
2025
2024
£
£
Remuneration for qualifying services
215,136
195,221
Company pension contributions to defined contribution schemes
5,600
5,626
PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 20 -
7
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
239,315
124,569
8
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
313,802
13,701
Deferred tax
Origination and reversal of timing differences
5,963
59,401
Total tax charge
319,765
73,102

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
1,561,786
1,477,141
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
390,447
369,285
Tax effect of expenses that are not deductible in determining taxable profit
5,086
437
Change in unrecognised deferred tax assets
(22)
(189,543)
Research and development tax credit
(75,000)
(105,494)
Tax at marginal rate
(746)
(1,583)
Taxation charge
319,765
73,102

The group used tax losses brought forward from 2023 against corporation tax profits in 2024 (being the Change in unrecognised deferred tax assets) and had £Nil tax losses to carry forward against corporation tax profits for 2025. The group has tax losses of £Nil available to carry forward against future corporation tax profits.

The group claims research and development tax relief.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 21 -
9
Dividends
2025
2024
2025
2024
Recognised as distributions to equity holders:
Per share
Per share
Total
Total
£
£
£
£
Ordinary shares
Interim paid
-
2.00
-
88,064
10
Intangible fixed assets
Group
Goodwill
£
Cost
At 1 April 2024 and 31 March 2025
127,500
Amortisation and impairment
At 1 April 2024 and 31 March 2025
127,500
Carrying amount
At 31 March 2025
-
0
At 31 March 2024
-
0
The company had no intangible fixed assets at 31 March 2025 or 31 March 2024.
PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 22 -
11
Tangible fixed assets
Group
Freehold property
Short leasehold property
Plant and Tackle
Office fittings & equipment
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 April 2024
1,382,503
22,291
1,253,838
156,534
350,938
3,166,104
Additions
12,472
-
0
61,343
10,943
12,500
97,258
Disposals
-
0
-
0
-
0
(875)
(103,624)
(104,499)
At 31 March 2025
1,394,975
22,291
1,315,181
166,602
259,814
3,158,863
Depreciation and impairment
At 1 April 2024
164,738
11,888
862,352
134,532
214,114
1,387,624
Depreciation charged in the year
1,140
1,486
92,501
7,499
38,621
141,247
Eliminated in respect of disposals
-
0
-
0
-
0
(875)
(103,621)
(104,496)
At 31 March 2025
165,878
13,374
954,853
141,156
149,114
1,424,375
Carrying amount
At 31 March 2025
1,229,097
8,917
360,328
25,446
110,700
1,734,488
At 31 March 2024
1,217,765
10,403
391,486
22,002
136,824
1,778,480
Company
Freehold property
£
Cost
At 1 April 2024
1,187,433
Additions
12,472
At 31 March 2025
1,199,905
Depreciation and impairment
At 1 April 2024
13,680
Depreciation charged in the year
1,140
At 31 March 2025
14,820
Carrying amount
At 31 March 2025
1,185,085
At 31 March 2024
1,173,753

Group freehold property of £1,229,097 includes £Nil (2024 : £Nil) relating to the net book value of premises on a customer's site.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 23 -
12
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
13
-
0
-
0
44,033
44,033
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 April 2024 and 31 March 2025
44,033
Carrying amount
At 31 March 2025
44,033
At 31 March 2024
44,033
13
Subsidiaries

Details of the company's subsidiaries at 31 March 2025 are as follows:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
P C Richardson and Company (Middlesbrough) Limited
Courville House, 34 Ellerbeck Court, Stokesley Business Park, Stokesley, North Yorkshire, TS9 5BT
Industrial maintenance
Ordinary
100.00
Stokesley Deli Limited
Courville House, 34 Ellerbeck Court, Stokesley Business Park, Stokesley, North Yorkshire, TS9 5PT
Restaurant and Delicatessen
Ordinary
100.00
14
Stocks
Group
Company
2025
2024
2025
2024
£
£
£
£
Raw materials and consumables
21,458
18,095
-
-
PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 24 -
15
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
725,332
2,840,895
-
0
-
0
Amounts recoverable on contracts
812,395
1,448,768
-
0
-
0
Other debtors
639,437
731,499
-
0
-
0
2,177,164
5,021,162
-
-
16
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
£
£
£
£
Payments received on account
144,517
840,288
-
0
-
0
Trade creditors
345,779
878,395
264
253
Corporation tax payable
313,802
13,701
25,807
8,848
Other taxation and social security
331,755
242,446
3,706
3,708
Other creditors
111,181
133,782
-
0
-
0
Accruals and deferred income
86,376
411,892
5,500
4,000
1,333,410
2,520,504
35,277
16,809

The group has an overdraft facility which is secured by a fixed and floating charge over assets of the group.

17
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
134,914
135,725
Other timing differences
(1,976)
(8,750)
132,938
126,975
Liabilities
Liabilities
2025
2024
Company
£
£
Accelerated capital allowances
42,571
39,657
PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
17
Deferred taxation
(Continued)
- 25 -
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 1 April 2024
126,975
39,657
Charge to profit or loss
5,963
2,914
Liability at 31 March 2025
132,938
42,571
18
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
201,921
162,233

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

19
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
44,032
44,032
44,032
44,032
20
Financial commitments, guarantees and contingent liabilities

Grants receivable may be repayable in part or in full if certain conditions associated with the grants are not met.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 26 -
21
Operating lease commitments
Lessee

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Group
Company
2025
2024
2025
2024
£
£
£
£
Within one year
77,316
79,999
-
-
Between two and five years
268,343
160,000
-
-
In over five years
31,452
70,000
-
-
377,111
309,999
-
-
22
Related party transactions
Transactions with related parties

During the year the group entered into the following transactions with related parties:

Remuneration
Dividends
2025
2024
2025
2024
£
£
£
£
Group
Entities with control, joint control or significant influence over the company
542,159
506,858
-
86,926
Other related parties
248,189
221,211
-
1,138
Company
Entities with control, joint control or significant influence over the company
-
-
-
86,926
Other related parties
-
-
-
1,138

At 31 March 2024 Mr P C Richardson owed the group £9,079. The amount repaid during the year was £Nil and Mr P C Richardson owed the group £9,079 at 31 March 2025. The loan is unsecured, interest free and repayable on demand.

23
Controlling party

The company was under the control of Mr P C Richardson throughout the current and previous year.

PCR HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 27 -
24
Cash generated from group operations
2025
2024
£
£
Profit after taxation
1,242,021
1,404,039
Adjustments for:
Taxation charged
319,765
73,102
Investment income
(239,315)
(124,569)
Gain on disposal of tangible fixed assets
(27,909)
(3,277)
Depreciation and impairment of tangible fixed assets
141,247
122,281
Movements in working capital:
(Increase)/decrease in stocks
(3,363)
1,322
Decrease/(increase) in debtors
2,843,998
(2,284,096)
(Decrease)/increase in creditors
(1,487,195)
1,652,487
Cash generated from operations
2,789,249
841,289
25
Analysis of changes in net funds - group
1 April 2024
Cash flows
31 March 2025
£
£
£
Cash at bank and in hand
8,245,591
2,945,523
11,191,114
2025-03-312024-04-01falsefalseCCH SoftwareCCH Accounts Production 2025.100Mrs T B RichardsonMr P C RichardsonMr G AblettMr D J RichardsonMiss E L RichardsonMr P G Flintoftfalse05572535bus:Consolidated2024-04-012025-03-31055725352024-04-012025-03-3105572535bus:Director22024-04-012025-03-3105572535bus:Director32024-04-012025-03-3105572535bus:Director42024-04-012025-03-3105572535bus:Director52024-04-012025-03-3105572535bus:CompanySecretary12024-04-012025-03-3105572535bus:Director12024-04-012025-03-3105572535bus:RegisteredOffice2024-04-012025-03-31055725352025-03-3105572535bus:Consolidated2023-04-012024-03-31055725352023-04-012024-03-3105572535bus:Consolidated2025-03-3105572535bus:Consolidated2024-03-3105572535core:Goodwillbus:Consolidated2025-03-3105572535core:Goodwillbus:Consolidated2024-03-31055725352024-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2025-03-3105572535core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2025-03-3105572535core:PlantMachinerybus:Consolidated2025-03-3105572535core:FurnitureFittingsbus:Consolidated2025-03-3105572535core:MotorVehiclesbus:Consolidated2025-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-03-3105572535core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-03-3105572535core:PlantMachinerybus:Consolidated2024-03-3105572535core:FurnitureFittingsbus:Consolidated2024-03-3105572535core:MotorVehiclesbus:Consolidated2024-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssets2025-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssets2024-03-3105572535core:ShareCapitalbus:Consolidated2025-03-3105572535core:ShareCapitalbus:Consolidated2024-03-3105572535core:OtherMiscellaneousReservebus:Consolidated2025-03-3105572535core:OtherMiscellaneousReservebus:Consolidated2024-03-3105572535core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-03-3105572535core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-03-3105572535core:ShareCapital2025-03-3105572535core:ShareCapital2024-03-3105572535core:RetainedEarningsAccumulatedLosses2025-03-3105572535core:RetainedEarningsAccumulatedLosses2024-03-3105572535core:ShareCapitalbus:Consolidated2023-03-3105572535core:ShareCapital2023-03-3105572535core:RetainedEarningsAccumulatedLosses2023-03-3105572535bus:Consolidated2023-03-3105572535core:Goodwill2024-04-012025-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssets2024-04-012025-03-3105572535core:LandBuildingscore:LongLeaseholdAssets2024-04-012025-03-3105572535core:PlantMachinery2024-04-012025-03-3105572535core:FurnitureFittings2024-04-012025-03-3105572535core:MotorVehicles2024-04-012025-03-3105572535core:UKTaxbus:Consolidated2024-04-012025-03-3105572535core:UKTaxbus:Consolidated2023-04-012024-03-3105572535bus:Consolidated12024-04-012025-03-3105572535bus:Consolidated12023-04-012024-03-3105572535core:Goodwillbus:Consolidated2024-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-03-3105572535core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-03-3105572535core:PlantMachinerybus:Consolidated2024-03-3105572535core:FurnitureFittingsbus:Consolidated2024-03-3105572535core:MotorVehiclesbus:Consolidated2024-03-3105572535bus:Consolidated2024-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssets2024-03-3105572535core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-04-012025-03-3105572535core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-04-012025-03-3105572535core:PlantMachinerybus:Consolidated2024-04-012025-03-3105572535core:FurnitureFittingsbus:Consolidated2024-04-012025-03-3105572535core:MotorVehiclesbus:Consolidated2024-04-012025-03-3105572535core:Subsidiary12024-04-012025-03-3105572535core:Subsidiary22024-04-012025-03-3105572535core:Subsidiary112024-04-012025-03-3105572535core:Subsidiary222024-04-012025-03-3105572535core:CurrentFinancialInstrumentsbus:Consolidated2025-03-3105572535core:CurrentFinancialInstrumentsbus:Consolidated2024-03-3105572535core:CurrentFinancialInstruments2025-03-3105572535core:CurrentFinancialInstruments2024-03-3105572535core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-03-3105572535core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-03-3105572535core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3105572535core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3105572535bus:PrivateLimitedCompanyLtd2024-04-012025-03-3105572535bus:FRS1022024-04-012025-03-3105572535bus:Audited2024-04-012025-03-3105572535bus:ConsolidatedGroupCompanyAccounts2024-04-012025-03-3105572535bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP